Shares of Summit Therapeutics surged 7.5% to $15.70 after partner Akeso announced that its experimental cancer drug beat Merck's blockbuster Keytruda — the world's best-selling medicine — on the ultimate measure: keeping patients alive longer. The question now is whether this data, generated entirely in China, can carry a pre-revenue company through an FDA decision just ten weeks away.
The Drug Beat the Gold Standard on What Matters Most. An independent monitoring committee found that ivonescimab delivered a "statistically significant and clinically meaningful" survival advantage over pembrolizumab (Keytruda) in first-line lung cancer patients. This follows earlier results showing a median delay in disease worsening of 11.14 months versus 5.82 months for Keytruda, a 49% reduction in the risk of progression or death. Survival is the endpoint that rewrites treatment guidelines and convinces insurance companies to pay. Detailed numerical results have not yet been released, with a presentation planned at an upcoming medical conference.
The FDA Decision in November Is the Real Inflection Point. The FDA set a decision deadline of November 14, 2026 for ivonescimab's first U.S. approval — initially in a narrower group of lung cancer patients whose tumors carry a specific gene mutation. That population alone includes over 14,000 eligible U.S. patients annually. Today's survival data from a different trial bolsters the drug's overall credibility, but HARMONi-2 was conducted entirely in China , which historically draws extra FDA scrutiny.
The Stock Is Priced for Enormous Success — With Zero Revenue. Summit carries a market capitalization around $12.9 billion with $0 in revenue and trailing twelve-month losses of $1.08 billion.
It ended Q2 2026 with $690.7 million in cash and no debt. That valuation only makes sense if ivonescimab can eventually chip away at Keytruda's franchise — a drug that generated $31.7 billion in 2025 alone.
Seventeen analysts rate SMMT a "Buy" with an average price target of $28.63, roughly double the current price.
The Pipeline Is Expanding, but the Risks Are Binary. Summit recently launched a bladder cancer trial with global site activations planned by late 2026 , and has added collaborations in kidney cancer. But the entire investment case hinges on one drug. If the FDA approves in November, the stock could leap. If it doesn't, there is very little beneath the valuation to break the fall.